#USA #Alameda #Stroke Treatment #Penumbra #THUNDERBOLT

THUNDER Study Confirms Penumbra's THUNDERBOLT System for Stroke Treatment

In a groundbreaking development for stroke care, Penumbra, Inc. has unveiled impressive results from its THUNDER study, showcasing the effectiveness and safety of its innovative THUNDERBOLT™ device. This pioneering technology, classified as a computer-assisted vacuum thrombectomy (CAVT™) system, is designed specifically for patients experiencing emergent large vessel occlusion (ELVO) stroke. Conducted across 29 centers in the United States, the THUNDER study enrolled a substantial number of 216 stroke patients, who were treated utilizing this cutting-edge approach.

The results of the study, presented recently at the Society of NeuroInterventional Surgery's 23rd Annual Meeting, create a compelling case for the THUNDERBOLT system's adoption in medical practice. With a striking 87.5% of treated cases achieving successful reperfusion—the re-establishment of blood flow defined as mTICI 2b-3—the data highlights a notable advancement in thrombectomy techniques. Furthermore, an astonishing 70.4% of patients achieved mTICI 2c-3, correlating with favorable functional outcomes and reducing complications, which is critical for patient recovery.

The study's co-principal investigator, Dr. Donald Frei, a neurointerventional radiologist at Swedish Medical Center, expressed enthusiasm about the findings, stating: "Mechanical thrombectomy remains the frontline treatment for stroke, yet current technologies often struggle with quick and complete clot removal at the occlusion site. The THUNDER study illustrates a high rate of complete clot ingestion with THUNDERBOLT, paired with a low incidence of complications, marking significant improvements in patient care."

One of the remarkable metrics from the trial revealed a median time-to-revascularization of only 20 minutes, while the complete clot ingestion rate stood at an impressive 83%. Furthermore, device-related serious adverse events occurred in just 2.8% of cases, with only a 0.9% incidence rate for symptomatic intracranial hemorrhage. Notably, the total mortality rate at 90 days was recorded at 11.7%, which notably sets a benchmark against other thrombectomy therapies.

Dr. David Fiorella, the other co-principal investigator and director at Stony Brook University's Cerebrovascular Center, indicated that THUNDERBOLT's use of modulated aspiration significantly enhances clot removal consistency. He noted, "The early experiences we gathered through the THUNDER study suggest that this technology could importantly transform stroke patient treatment outcomes."

The THUNDER study follows a single-arm, prospective design, and the data affirm the CAVT technology as not only innovative but also essential for effective thrombectomy procedures. Through the combined capabilities of THUNDERBOLT, healthcare providers can expect to achieve quick and precise revascularization, further extending their treatment options for stroke care.

As acute ischemic stroke (AIS) continues to present a global health crisis, responsible for approximately 87% of all strokes affecting around 68 million people worldwide, the demand for effective treatments is crucial. Approximately 20% to 42% of AIS cases are classified as ELVO, reinforcing the importance of advancements in this area. THUNDERBOLT has also obtained U.S FDA clearance and CE Mark in Europe, solidifying its position among leading thrombectomy devices.

Penumbra, Inc. remains committed to developing pioneering medical solutions focusing on severe health challenges including ischemic strokes and venous thromboembolism. By delivering advanced technologies like THUNDERBOLT and CAVT, the company supports healthcare practitioners globally, ultimately improving clinical outcomes and patients' quality of life. For further information about their innovative offerings, visit Penumbra's website.